| Dr David L Ross, MD | |
|
127 Crestview Park Dr, Dickson, TN 37055-2850 | |
| (615) 446-5121 | |
| (615) 441-4507 |
| Full Name | Dr David L Ross |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 24 Years |
| Location | 127 Crestview Park Dr, Dickson, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073516001 | NPI | - | NPPES |
| 3884779 | Medicaid | TN | |
| 4066286 | Other | TN | BLUE CROSS BLUE SHIELD TN |
| P00016815 | Other | RAILROAD MEDICARE PIN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MD37418 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Amedisys Home Health | Nashville, TN | Home health agency |
| Home Care Solutions | Nashville, TN | Home health agency |
| Tennessee Quality Care - Home Health | Parsons, TN | Home health agency |
| Tristar Horizon Medical Center | Dickson, TN | Hospital |
| Three Rivers Hospital | Waverly, TN | Hospital |
| Steward Rockledge Hospital | Rockledge, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dickson Medical Associates, Pc | 3971408774 | 53 |
News Archive
The public company Moberg Derma AB has through its U.S. distributor Alterna LLC received a first order from the world's largest retail chain, Walmart, for Emtrix - its treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis.
Many cancer therapies target specific proteins that proliferate on the outside of some cancer cells, but the therapies are imperfect and the cancer does not always respond. Since it is beneficial for doctors to know as soon as possible how a cancer is affected by treatment, researchers from Vanderbilt University are striving to design tests that assess treatment response rapidly, accurately, and cost-effectively.
Working together, Johns Hopkins biomedical engineers and neurosurgeons report that they have created tiny, biodegradable "nanoparticles" able to carry DNA to brain cancer cells in mice.
Pfizer Inc. today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean change in HAQ-DI, respectively, versus placebo at three months.
Stroke is one of the most common neurological disorders worldwide. Many stroke survivors are left with serious health problems. Some patients, for example, find themselves unable to perceive one side of their body and can have problems seeing, hearing and feeling on that side.
› Verified 3 days ago
| Entity Name | Dickson Medical Associates, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568464873 PECOS PAC ID: 3971408774 Enrollment ID: O20031204000828 |
News Archive
The public company Moberg Derma AB has through its U.S. distributor Alterna LLC received a first order from the world's largest retail chain, Walmart, for Emtrix - its treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis.
Many cancer therapies target specific proteins that proliferate on the outside of some cancer cells, but the therapies are imperfect and the cancer does not always respond. Since it is beneficial for doctors to know as soon as possible how a cancer is affected by treatment, researchers from Vanderbilt University are striving to design tests that assess treatment response rapidly, accurately, and cost-effectively.
Working together, Johns Hopkins biomedical engineers and neurosurgeons report that they have created tiny, biodegradable "nanoparticles" able to carry DNA to brain cancer cells in mice.
Pfizer Inc. today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean change in HAQ-DI, respectively, versus placebo at three months.
Stroke is one of the most common neurological disorders worldwide. Many stroke survivors are left with serious health problems. Some patients, for example, find themselves unable to perceive one side of their body and can have problems seeing, hearing and feeling on that side.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David L Ross, MD 127 Crestview Park Dr, Dickson, TN 37055-2850 Ph: (615) 446-5121 | Dr David L Ross, MD 127 Crestview Park Dr, Dickson, TN 37055-2850 Ph: (615) 446-5121 |
News Archive
The public company Moberg Derma AB has through its U.S. distributor Alterna LLC received a first order from the world's largest retail chain, Walmart, for Emtrix - its treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis.
Many cancer therapies target specific proteins that proliferate on the outside of some cancer cells, but the therapies are imperfect and the cancer does not always respond. Since it is beneficial for doctors to know as soon as possible how a cancer is affected by treatment, researchers from Vanderbilt University are striving to design tests that assess treatment response rapidly, accurately, and cost-effectively.
Working together, Johns Hopkins biomedical engineers and neurosurgeons report that they have created tiny, biodegradable "nanoparticles" able to carry DNA to brain cancer cells in mice.
Pfizer Inc. today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean change in HAQ-DI, respectively, versus placebo at three months.
Stroke is one of the most common neurological disorders worldwide. Many stroke survivors are left with serious health problems. Some patients, for example, find themselves unable to perceive one side of their body and can have problems seeing, hearing and feeling on that side.
› Verified 3 days ago
Luma Kharabsheh, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 127 Crestview Park Dr, Dickson, TN 37055 Phone: 615-446-5121 Fax: 615-446-1357 | |
Winifred Cecelia Lassiter, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 301 W End Ave, Dickson, TN 37055 Phone: 615-446-2839 | |
Dr. Jeffrey Alan Culp, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 127 Crestview Park Dr Ste 205, Dickson, TN 37055 Phone: 615-441-4500 Fax: 615-908-1237 | |
Dr. Michael Lance Smitherman, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 127 Crestview Park Dr Ste 206, Dickson, TN 37055 Phone: 615-446-1377 Fax: 615-446-1367 | |
Mohammad A Alsoub, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 111 Highway 70 E Ste 102, Dickson, TN 37055 Phone: 615-375-1531 Fax: 615-375-1526 | |
Dr. David J Blazer, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 113 Highway 70 E, Dickson, TN 37055 Phone: 615-441-4450 Fax: 615-446-1357 |